Elimination of smooth muscle cells in experimental restenosis: targeting of fibroblast growth factor receptors
- PMID: 1323129
- PMCID: PMC49665
- DOI: 10.1073/pnas.89.15.7159
Elimination of smooth muscle cells in experimental restenosis: targeting of fibroblast growth factor receptors
Abstract
Factors in plasma and platelets do not fully account for the proliferation of smooth muscle cells in vascular injury, implying that additional factors are involved. Recently, we and others have observed that vascular injury regulates basic fibroblast growth factor, suggesting a further role for this pleiotropic factor. We report here that injury of rat arteries leads to an increase in fibroblast growth factor receptors in vascular smooth muscle cells. This up-regulation makes smooth muscle cells susceptible, in vitro and in vivo, to the lethal effects of a conjugate of basic fibroblast growth factor with the ribosome inactivator saporin. Saporin alone has no effect, whereas the conjugate kills proliferating, but not quiescent, smooth muscle cells in vitro. In vivo, one to three doses inhibit neointimal proliferation but have no apparent effect on the uninjured artery. Thus, the up-regulation of fibroblast growth factor receptors in vascular injury suggests new therapeutic possibilities for such refractory conditions as restenosis following balloon angioplasty.
Similar articles
-
Vascular smooth muscle cell cytotoxicity and sustained inhibition of neointimal formation by fibroblast growth factor 2-saporin fusion protein.Circ Res. 1997 Apr;80(4):542-50. doi: 10.1161/01.res.80.4.542. Circ Res. 1997. PMID: 9118485
-
Fibroblast growth factor-2-toxin induced cytotoxicity: differential sensitivity of co-cultured vascular smooth muscle cells and endothelial cells.Atherosclerosis. 1998 Apr;137(2):277-89. doi: 10.1016/s0021-9150(97)00284-0. Atherosclerosis. 1998. PMID: 9622271
-
Fibroblast growth factor complexed to the cytotoxin saporin is growth inhibitory but not cytotoxic for embryonal carcinoma cells.Cytotechnology. 1993;13(2):69-78. doi: 10.1007/BF00749933. Cytotechnology. 1993. PMID: 7764580
-
Factors controlling the development of arterial lesions after injury.Circulation. 1992 Dec;86(6 Suppl):III43-6. Circulation. 1992. PMID: 1424050 Review.
-
Role of thromboxane A2 in mitogenesis of vascular smooth muscle cells.Agents Actions Suppl. 1997;48:42-62. doi: 10.1007/978-3-0348-7352-9_3. Agents Actions Suppl. 1997. PMID: 9177099 Review.
Cited by
-
Exogenous HSP70 becomes cell associated, but not internalized, by stressed arterial smooth muscle cells.In Vitro Cell Dev Biol Anim. 1993 Oct;29A(10):807-12. doi: 10.1007/BF02634348. In Vitro Cell Dev Biol Anim. 1993. PMID: 8118616
-
Transluminal angioplasty for arteriosclerotic disease of the distal vertebral and basilar arteries.J Neurol Neurosurg Psychiatry. 1996 Apr;60(4):377-81. doi: 10.1136/jnnp.60.4.377. J Neurol Neurosurg Psychiatry. 1996. PMID: 8774399 Free PMC article.
-
Fibroblast growth factor receptor 4 polymorphism is associated with increased risk and poor prognosis of non-Hodgkin's lymphoma.Tumour Biol. 2014 Apr;35(4):2997-3002. doi: 10.1007/s13277-013-1386-7. Epub 2013 Nov 19. Tumour Biol. 2014. PMID: 24248544
-
Modification of alternative messenger RNA splicing of fibroblast growth factor receptors in human cardiac allografts during rejection.J Clin Invest. 1994 Sep;94(3):992-1003. doi: 10.1172/JCI117466. J Clin Invest. 1994. PMID: 7521891 Free PMC article.
-
FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis.Blood. 2006 Jan 1;107(1):126-31. doi: 10.1182/blood-2005-06-2460. Epub 2005 Sep 13. Blood. 2006. PMID: 16160009 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources